High Risk Stocks To Buy 2017 -

: This biotechnology firm was a standout, posting a 426% return in 2017. Its growth was driven by positive clinical trial results for its cholesterol-reducing drug candidate.

The following stocks represented some of the most successful speculative plays for the year: high risk stocks to buy 2017

For investors in 2017, the "high-risk, high-reward" segment of the market was defined by a strong rebound in energy, explosive breakthroughs in biotechnology, and the rising dominance of high-growth technology. While the broader market saw a lack of volatility, with the S&P 500 rising roughly 20% and the Nasdaq nearly 30%, these specific sectors offered triple-digit gains for those willing to stomach higher volatility. : This biotechnology firm was a standout, posting

: Stocks like Freeport-McMoRan (FCX) and Cameco (CCJ) were considered high-risk due to volatile commodity prices. FCX, in particular, was viewed as a speculative "survival" play as it wrestled with high debt levels relative to cash flow. While the broader market saw a lack of

: The maker of Invisalign benefited from a near-monopoly on invisible braces, seeing a 131% increase as it expanded its training to thousands of dentists globally.

: Nine of the top ten performing stocks of the year were in the biotech sector. Companies like Vertex Pharmaceuticals (VRTX) (up 97%) and Dynavax Technologies (DVAX) (up 373%) succeeded based on FDA approvals and breakthrough trial data.